The FDA is nearing a decision on leadership for its Center for Biologics Evaluation and Research (CBER), with sources telling Endpoints News that the agency is narrowing its search for a new director. The report ties the selection process to fallout from the controversial tenure of outgoing CBER leader Vinay Prasad. CBER oversees pivotal review work for biologics and vaccines, making the leadership appointment relevant to how the agency prioritizes scientific and policy decisions. A shift in CBER leadership can also affect internal review cadence and interpretation of regulatory expectations for emerging biologics modalities.